Therapeutic Potential of Umbilical Cord Blood Cells for Type 1 Diabetes Mellitus

Ben He,Xia Li,Haibo Yu,Zhiguang Zhou
DOI: https://doi.org/10.1111/1753-0407.12286
IF: 4.53
2015-01-01
Journal of Diabetes
Abstract:Type 1 diabetes mellitus ( T1DM ) is a chronic disorder that results from autoimmune‐mediated destruction of pancreatic islet β ‐cells. However, to date, no conventional intervention has successfully treated the disease. The optimal therapeutic method for T1DM should effectively control the autoimmunity, restore immune homeostasis, preserve residual β ‐cells, reverse β ‐cell destruction, and protect the regenerated insulin‐producing cells against re‐attack. Umbilical cord blood is rich in regulatory T ( T reg ) cells and multiple types of stem cells that exhibit immunomodulating potential and hold promise in their ability to restore peripheral tolerance towards pancreatic islet β ‐cells through remodeling of immune responses and suppression of autoreactive T cells. Recently, reinfusion of autologous umbilical cord blood or immune cells from cord blood has been proposed as a novel therapy for T1DM , with the advantages of no risk to the donors, minimal ethical concerns, a low incidence of graft‐versus‐host disease and easy accessibility. In this review, we revisit the role of autologous umbilical cord blood or immune cells from cord blood‐based applications for the treatment of T1DM .
What problem does this paper attempt to address?